Cargando…

A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer

OBJECTIVE: The role of HMG-CoA reductase (HMGCR) in relation to prognostic and treatment predictive information of HER2 positive breast cancer has been newly explored. In this study, we aimed to determine the expression of HMGCR in HER2 immunohistochemistry (IHC) scores of 2+ and 3+ breast cancer an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Malisalaora, Mohd Nafi, Siti Norasikin, Jaafar, Hasnan, Paiman, Noorasmaliza Md
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607074/ https://www.ncbi.nlm.nih.gov/pubmed/34319025 http://dx.doi.org/10.31557/APJCP.2021.22.7.2043

Ejemplares similares

Cellular and Molecular Changes in MNU-Induced Breast Tumours Injected with PF4 or bFGF
por: Nafi, Siti Norasikin Mohd, et al.
Publicado: (2017)

Andrographolide is an Alternative Treatment to Overcome Resistance in ER-Positive Breast Cancer via Cholesterol Biosynthesis Pathway
por: Rajaratinam, Harishini, et al.
Publicado: (2019)

nNav1.5 expression is associated with glutamate level in breast cancer cells
por: Azahar, Irfan Irsyad, et al.
Publicado: (2022)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
por: Nafi, Siti Norasikin Mohd, et al.
Publicado: (2014)

Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
por: Payandeh, Mehrdad, et al.
Publicado: (2017)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients
por: Radziuviene, Gedmante, et al.
Publicado: (2021)

Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers
por: Jusoh, A. Rashid, et al.
Publicado: (2021)

The concordance between IHC and ISH for HER-2 testing in breast cancer in Nakhon Pathom Hospital, Thailand, based on the ASCO/CAP 2018 guidelines: a retrospective study
por: Thambamroong, Tawasapon
Publicado: (2022)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023)

Exploring Two Protocols of FISH Using Cytocell SYT-SSX Probe on Formalin Fixed Paraffin Embedded Tissue Sections
por: Yajid, Aidy Irman, et al.
Publicado: (2020)

Immunohistochemistry as a detection tool for ion channels involved in dental pain signaling
por: Ramli, Rosmaliza, et al.
Publicado: (2022)

Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012)

Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients
por: Xie, Suhong, et al.
Publicado: (2022)

Estrogen Receptor-Negative Breast Ductal Carcinoma: Clinicopathological Features and Mib-1 (Ki-67) Proliferative Index Association
por: MdPaiman, Noorasmaliza, et al.
Publicado: (2014)

Predicting Effects of Clinicopathological Variables on Her2 Gene Amplification by Chromogenic in situ Hybridization (CISH) in IHC Her2 (2+) Breast Cancer Patients; A Study from Iran
por: Hashemi Bahremani, Mohammad, et al.
Publicado: (2020)

A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification
por: Xu, Bin, et al.
Publicado: (2023)

Immunohistochemical expression of apolipoprotein B and 4-hydroxynonenal proteins in colorectal carcinoma patients: a retrospective study
por: Ng, Phei Ying, et al.
Publicado: (2023)

Anti-HMGCR Myopathy
por: Mohassel, Payam, et al.
Publicado: (2018)

Macrodissection prior to Closed System RT-qPCR is not necessary for Estrogen Receptor and HER2 Concordance with IHC/FISH in Breast Cancer
por: Gupta, Swati, et al.
Publicado: (2018)

Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification
por: Varga, Zsuzsanna, et al.
Publicado: (2014)

Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment—a retrospective cohort study
por: Wang, Jiabin, et al.
Publicado: (2022)

The Unique Biology behind the Early Onset of Breast Cancer
por: Siddig, Alaa, et al.
Publicado: (2021)

Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques
por: Nedjadi, Taoufik, et al.
Publicado: (2016)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network
por: Borley, A, et al.
Publicado: (2014)

HER2 Basolateral versus Circumferential IHC Expression Is Dependent on Polarity and Differentiation of Epithelial Cells in Gastric/GE Adenocarcinoma
por: Pervez, Shahid, et al.
Publicado: (2018)

Comparison of Immunohistochemical Methods (IHC) and Fluorescent in Situ Hybridization (FISH) in the Detection of HER 2 /Neu Gene in Kurdish Patients with Breast Cancer in Western Iran
por: Aznab, Mozafar, et al.
Publicado: (2022)

Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma
por: Aznab, Mozaffar, et al.
Publicado: (2020)

Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
por: Ma, Shizhan, et al.
Publicado: (2019)

Anti-HMGCR antibodies in systemic sclerosis
por: Hudson, Marie, et al.
Publicado: (2016)

Endocan-microvascular Density in Primary Ovarian Carcinoma
por: Baba, Farahlina, et al.
Publicado: (2022)

Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: Experience at tertiary cancer care centre
por: Panigrahi, Manoj Kumar, et al.
Publicado: (2017)

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
por: Kurbel, Sven, et al.
Publicado: (2017)

Allred Scoring of ER-IHC Stained Whole-Slide Images for Hormone Receptor Status in Breast Carcinoma
por: Ahmad Fauzi, Mohammad Faizal, et al.
Publicado: (2022)

Comparing the Biology of Young versus Old Age Estrogen-Receptor-Positive Breast Cancer through Gene and Protein Expression Analyses
por: Siddig, Alaa, et al.
Publicado: (2023)

Statin use in patients with non‐HMGCR idiopathic inflammatory myopathies: A retrospective study
por: Bae, Sangmee Sharon, et al.
Publicado: (2020)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx
por: Kalpakoff, Megan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pu18hnojvb3f422sinu91kvhmt